Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.

Reinshagen M, Schütz E, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Kruis W, Oellerich M, von Ahsen N.

Clin Chem. 2007 Jul;53(7):1306-14.

2.

High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.

van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML.

Aliment Pharmacol Ther. 2012 May;35(10):1181-9. doi: 10.1111/j.1365-2036.2012.05084.x.

3.

Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.

Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K.

Scand J Gastroenterol. 2004 Nov;39(11):1105-12.

PMID:
15545169
5.

Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.

Banerjee S, Bishop WP.

J Pediatr Gastroenterol Nutr. 2006 Sep;43(3):324-30.

PMID:
16954954
6.

The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.

Gao X, Zhang FB, Ding L, Liu H, Wang XD, Chen BL, Bi HC, Xiao YL, Zhao LZ, Chen MH, Huang M, Hu PJ.

Eur J Gastroenterol Hepatol. 2012 Aug;24(8):958-64. doi: 10.1097/MEG.0b013e3283545ae3.

PMID:
22664938
7.

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.

Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM.

Clin Gastroenterol Hepatol. 2004 May;2(5):410-7.

PMID:
15118980
8.

Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.

Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM.

Intern Med J. 2005 Oct;35(10):580-5.

PMID:
16207256
9.

The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.

Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.

J Crohns Colitis. 2014 Feb;8(2):120-8. doi: 10.1016/j.crohns.2013.07.004.

PMID:
23932783
10.

Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.

Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, Romberg-Camps MJ, Stronkhorst A, Bus P, Bos LP, Hooymans PM, Stockbrügger RW, Neef C, Masclee AA.

J Crohns Colitis. 2012 Jul;6(6):698-707. doi: 10.1016/j.crohns.2011.12.003.

PMID:
22398098
11.

Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.

Armstrong L, Sharif JA, Galloway P, McGrogan P, Bishop J, Russell RK.

Aliment Pharmacol Ther. 2011 Nov;34(9):1106-14. doi: 10.1111/j.1365-2036.2011.04848.x.

12.

Pharmacological monitoring of azathioprine therapy.

Reuther LO, Sonne J, Larsen NE, Larsen B, Christensen S, Rasmussen SN, Tofteng F, Haaber A, Johansen N, Kjeldsen J, Schmiegelow K.

Scand J Gastroenterol. 2003 Sep;38(9):972-7.

PMID:
14531535
13.

Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells.

Bergan S, Rugstad HE, Klemetsdal B, Giverhaug T, Bentdal O, Sødal G, Hartmann A, Aarbakke J, Stokke O.

Ther Drug Monit. 1997 Jun;19(3):318-26.

PMID:
9200774
14.

Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.

Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y.

J Gastroenterol Hepatol. 2008 Sep;23(9):1373-7. doi: 10.1111/j.1440-1746.2008.05419.x.

PMID:
18662197
15.

Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.

Lennard L, Cartwright CS, Wade R, Richards SM, Vora A.

Br J Clin Pharmacol. 2013 Jul;76(1):125-36. doi: 10.1111/bcp.12066.

17.

Thiopurine metabolite ratios for monitoring therapy in pediatric Crohn disease.

Kopylov U, Amre D, Theoret Y, Deslandres C, Seidman EG.

J Pediatr Gastroenterol Nutr. 2014 Oct;59(4):511-5. doi: 10.1097/MPG.0000000000000455.

PMID:
24918978
18.

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team..

Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002.

PMID:
26072396
19.

Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.

Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.

Ther Drug Monit. 2007 Feb;29(1):1-5.

PMID:
17304143
20.

Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.

Belaiche J, Desager JP, Horsmans Y, Louis E.

Scand J Gastroenterol. 2001 Jan;36(1):71-6.

PMID:
11218242

Supplemental Content

Support Center